Shots: Glenmark is concluding the final, national phase of its MAA process to enable launch of its innovative nasal spray, Ryaltris (olopatadine hydrochloride, 665mcg and mometasone furoate, 25mcg), in 17 […]readmore
Tags : Ryaltris
Shots: Glenmark to receive up front, regulatory & commercial milestones along with royalties on sales of Ryaltris in the licensed territory. Glenmark will continue the development of the therapy and […]readmore
Shots: Glenmark to receive upfront, milestones and royalties on sales from Yuhan. Yuhan to get exclusive commercialization rights for Glenmark’s Ryaltris in South Korea Yuhan will be responsible for its […]readmore